166 related articles for article (PubMed ID: 21656741)
1. Progression-free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy.
Heng DY; Xie W; Bjarnason GA; Vaishampayan U; Tan MH; Knox J; Donskov F; Wood L; Kollmannsberger C; Rini BI; Choueiri TK
Cancer; 2011 Jun; 117(12):2637-42. PubMed ID: 21656741
[TBL] [Abstract][Full Text] [Related]
2. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.
Halabi S; Rini B; Escudier B; Stadler WM; Small EJ
Cancer; 2014 Jan; 120(1):52-60. PubMed ID: 24347384
[TBL] [Abstract][Full Text] [Related]
3. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
5. Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Iacovelli R; Lanoy E; Albiges L; Escudier B
BJU Int; 2012 Dec; 110(11):1747-53. PubMed ID: 23106948
[TBL] [Abstract][Full Text] [Related]
6. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with metastatic renal cell carcinoma receiving targeted therapy.
Zhang GM; Zhu Y; Gu WJ; Zhang HL; Shi GH; Ye DW
Int J Clin Oncol; 2016 Apr; 21(2):373-378. PubMed ID: 26335242
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Rebibo JD; Pfister C; Giwerc A; Defortescu G; Gouerant S; Di Fiore F; Nouhaud FX
Prog Urol; 2016 Jan; 26(1):16-23. PubMed ID: 26455779
[TBL] [Abstract][Full Text] [Related]
9. Survival prognoses of Heng intermediate-risk patients with metastatic renal cell carcinoma treated with immunotherapy or targeted therapy: A real-world, single-center retrospective study.
Kim SH; Lee DE; Joung JY; Seo HK; Lee KH; Chung J
Investig Clin Urol; 2020 Mar; 61(2):146-157. PubMed ID: 32158965
[TBL] [Abstract][Full Text] [Related]
10. A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Kim SH; Kim S; Joo J; Seo HK; Joung JY; Lee KH; Chung J
BMC Cancer; 2016 Aug; 16():577. PubMed ID: 27484254
[TBL] [Abstract][Full Text] [Related]
11. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
12. Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Cai W; Zhang J; Chen Y; Kong W; Huang Y; Huang J; Zhou L
Chin J Cancer; 2017 May; 36(1):47. PubMed ID: 28521783
[TBL] [Abstract][Full Text] [Related]
13. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted Drugs.
Lee CH; Hötker AM; Voss MH; Feldman DR; Woo KM; Patil S; Coskey DT; Akin O; Hsieh JJ; Motzer RJ
Clin Genitourin Cancer; 2016 Feb; 14(1):56-62. PubMed ID: 26404107
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Kroeger N; Pantuck AJ; Wells JC; Lawrence N; Broom R; Kim JJ; Srinivas S; Yim J; Bjarnason GA; Templeton A; Knox J; Bernstein E; Smoragiewicz M; Lee J; Rini BI; Vaishampayan UN; Wood LA; Beuselinck B; Donskov F; Choueiri TK; Heng DY
Eur Urol; 2015 Sep; 68(3):506-15. PubMed ID: 25524810
[TBL] [Abstract][Full Text] [Related]
16. Everolimus-induced pneumonitis associates with favourable outcome in patients with metastatic renal cell carcinoma.
Penttilä P; Donskov F; Rautiola J; Peltola K; Laukka M; Bono P
Eur J Cancer; 2017 Aug; 81():9-16. PubMed ID: 28586749
[TBL] [Abstract][Full Text] [Related]
17. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
18. Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Ishihara H; Yagisawa T; Kondo T; Omae K; Takagi T; Iizuka J; Kobayashi H; Tanabe K
Int J Clin Oncol; 2017 Feb; 22(1):126-135. PubMed ID: 27549785
[TBL] [Abstract][Full Text] [Related]
19. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Antoun S; Lanoy E; Iacovelli R; Albiges-Sauvin L; Loriot Y; Merad-Taoufik M; Fizazi K; di Palma M; Baracos VE; Escudier B
Cancer; 2013 Sep; 119(18):3377-84. PubMed ID: 23801109
[TBL] [Abstract][Full Text] [Related]
20. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy.
Richey SL; Culp SH; Jonasch E; Corn PG; Pagliaro LC; Tamboli P; Patel KK; Matin SF; Wood CG; Tannir NM
Ann Oncol; 2011 May; 22(5):1048-1053. PubMed ID: 21115604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]